Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.

The company's management team, including Chief Executive Officer Ben Zeskind and Chief Scientific Officer Brett Hall, will deliver a presentation on February 12 from 2:40 – 3:10 pm ET in Track 2. During the conference, they will discuss Immuneering's pipeline, platform, and business strategy.

The presentation will be accessible through a live webcast and will be archived in the Investor Relations section of Immuneering's website under Events & Presentations.

News Market Reaction

+3.72%

1 alert

+3.72% News Effect

On the day this news was published, IMRX gained 3.72%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer.

Format: Company Presentation and 1x1 Investor Meetings

Date/Time: February 12 from 2:40 – 3:10 pm ET in Track 2

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent
gina@nugentcommunications.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com

FAQ

When is Immuneering (IMRX) presenting at the Oppenheimer Healthcare Conference 2025?

Immuneering will present on February 12, 2025, from 2:40 – 3:10 pm ET in Track 2 at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference.

How can investors watch Immuneering's (IMRX) Oppenheimer conference presentation?

Investors can watch the presentation via live webcast, which will be available and archived in the Investor Relations section of Immuneering's website under Events & Presentations.

What topics will Immuneering (IMRX) discuss at the Oppenheimer Healthcare Conference?

Immuneering will discuss the company's pipeline, platform, and business strategy during their presentation at the conference.

Which Immuneering executives are participating in the Oppenheimer Healthcare Conference 2025?

CEO Ben Zeskind and Chief Scientific Officer Brett Hall will represent Immuneering at the conference.